|
|
|
Volumn 4, Issue 11 Suppl 23, 2006, Pages
|
|
Angiogenesis inhibition in the treatment of lung cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CARBOPLATIN;
ERLOTINIB;
MONOCLONAL ANTIBODY;
PACLITAXEL;
PROTEIN KINASE INHIBITOR;
QUINAZOLINE DERIVATIVE;
VASCULOTROPIN A;
BLEEDING;
CHEMICALLY INDUCED DISORDER;
DISEASE FREE SURVIVAL;
DRUG ANTAGONISM;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
MORTALITY;
NEOVASCULARIZATION (PATHOLOGY);
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
RISK FACTOR;
SURVIVAL RATE;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE III AS TOPIC;
DISEASE-FREE SURVIVAL;
HEMORRHAGE;
HUMANS;
LUNG NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
PACLITAXEL;
PROTEIN KINASE INHIBITORS;
QUINAZOLINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK FACTORS;
SURVIVAL RATE;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 34347369232
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (15)
|
|
References (0)
|
